Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 87Advanced Solid Tumor 80Advanced Solid Tumors 70Mesothelioma, Malignant 41Solid Tumor, Adult 29Mesothelioma 28Solid Tumors 24Unspecified Adult Solid Tumor, Protocol Specific 21Retinoblastoma 19Carcinoma, Non-Small-Cell Lung 11Stomach Neoplasms 9Ovarian Neoplasms 8Advanced Malignant Solid Tumors 7Advanced Malignant Solid Tumor 7Pancreatic Neoplasms 6Melanoma 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Lung Neoplasms 5Locally Advanced or Metastatic Solid Tumors 5Esophageal Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pleural Effusion, Malignant 4Malignant Solid Tumors 4Lymphoma 4Carcinoma, Hepatocellular 4Unspecified Childhood Solid Tumor, Protocol Specific 3

Interventions

Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Bone Metastasis From Solid Tumors × Other solid neoplasm × Clear all
NCT04494373 2020-08-04

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
154 enrolled
Other solid neoplasm

Bone Metastasis From Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡